Inhibition of the PD-1 immune checkpoint and the development of heart failure in the presence of prior cardiac ischemia.
Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment. However, their use often leads to cardiovascular adverse effects, including cardiac dysfunction. Here, we hypothesized that a p...
Balancing Clinical and Ethical Considerations Related to Placebo Use in Trials of Incretin-Based Therapies in Heart Failure.
Recent trials have shown that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dual gastric inhibitory polypeptide/GLP-1 RAs improve symptoms and functional capacity in patients with heart fa...
Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study.
Excess adiposity, most commonly indexed through body mass index (BMI), is strongly associated with the development of heart failure (HF). Weight loss therapies improve outcomes in patients with obesit...
Outcomes of Cardiac Resynchronization Therapy in Adults with Congenital Heart Disease and Heart Failure with Reduced Ejection Fraction.
There are limited data about the role of cardiac resynchronization therapy (CRT) in adults with congenital heart disease (CHD) and heart failure with reduced ejection fraction (HFrEF). (i) Assess the ...
Kidney Disease and Heart Failure: Recent Advances and Current Challenges: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Heart failure (HF) and chronic kidney disease (CKD) frequently coexist, which elevates the risks of hospitalization, disease progression, and death. Despite advances in treating each condition indepen...
Using Days Alive and Out of Hospital as the Study Endpoint in Cardiovascular Heart Failure Clinical Trials.
Socioeconomic Correlates of Incident Heart Failure and Consequent Mortality: The All of Us Program.
Although socioeconomic status (SES) is a known determinant of cardiovascular disease, the independent risks of incident heart failure (HF) and consequent mortality portended by individual and neighbor...
Excess and Dysfunctional Fat as a Primary Driver of Heart Failure With Preserved Ejection Fraction: From Institutional Recognition to Clinical Integration.
Epidemiological and Mendelian randomization studies demonstrate a strong link between central obesity, visceral adiposity, and heart failure with preserved ejection fraction (HFpEF). The AHA (American...
Interchangeability of the KCCQ-12 and KCCQ-23 Across >18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure.
The 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ-23) is formally qualified by the Food and Drug Administration as a valid patient-reported outcome measure for use in heart failure (HF) clini...
Multi-Organ Physiologic Deficits During Exercise Identify Clinical and Molecular Predisposition to Heart Failure with Preserved Ejection Fraction.
Exercise unmasks limitations in multi-organ system reserve capacity characteristic of heart failure with preserved ejection fraction (HFpEF). However, the metabolic and genetic underpinnings of exerci...
Management of dyslipidaemia in patients with comorbidities - facing the challenge: Heart failure.
The combined prevalence of heart failure (HF) with coronary atherosclerosis is frequent and often causally linked. The aim of this review is to elucidate whether lipid lowering drugs (LLDs) are useful...